Literature DB >> 29419406

Microglial Phenotypes and Functions in Multiple Sclerosis.

Elaine O'Loughlin1, Charlotte Madore1, Hans Lassmann2, Oleg Butovsky1,3.   

Abstract

Microglia are the resident immune cells that constantly survey the central nervous system. They can adapt to their environment and respond to injury or insult by altering their morphology, phenotype, and functions. It has long been debated whether microglial activation is detrimental or beneficial in multiple sclerosis (MS). Recently, the two opposing yet connected roles of microglial activation have been described with the aid of novel microglial markers, RNA profiling, and in vivo models. In this review, microglial phenotypes and functions in the context of MS will be discussed with evidence from both human pathological studies, in vitro and in vivo models. Microglial functional diversity-phagocytosis, antigen presentation, immunomodulation, support, and repair-will also be examined in detail. In addition, this review discusses the emerging evidence for microglia-related targets as biomarkers and therapeutic targets for MS.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29419406      PMCID: PMC5793738          DOI: 10.1101/cshperspect.a028993

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  181 in total

1.  Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system.

Authors:  Iftach Shaked; Ziv Porat; Roman Gersner; Jonathan Kipnis; Michal Schwartz
Journal:  J Neuroimmunol       Date:  2004-01       Impact factor: 3.478

Review 2.  Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier.

Authors:  H Lassmann; K Rössler; F Zimprich; K Vass
Journal:  Brain Pathol       Date:  1991-01       Impact factor: 6.508

3.  Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis.

Authors:  Laura A N Peferoen; Daphne Y S Vogel; Kimberley Ummenthum; Marjolein Breur; Priscilla D A M Heijnen; Wouter H Gerritsen; Regina M B Peferoen-Baert; Paul van der Valk; Christine D Dijkstra; Sandra Amor
Journal:  J Neuropathol Exp Neurol       Date:  2015-01       Impact factor: 3.685

4.  Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis.

Authors:  R M Nagra; B Becher; W W Tourtellotte; J P Antel; D Gold; T Paladino; R A Smith; J R Nelson; W F Reynolds
Journal:  J Neuroimmunol       Date:  1997-09       Impact factor: 3.478

Review 5.  Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies.

Authors:  Johannes M van Noort; Peter J van den Elsen; Jack van Horssen; Jeroen J G Geurts; Paul van der Valk; Sandra Amor
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-02       Impact factor: 4.388

6.  Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

Authors:  Michael Webb; Chui-Se Tham; Fen-Fen Lin; Karen Lariosa-Willingham; Naichen Yu; Jeffrey Hale; Suzanne Mandala; Jerold Chun; Tadimeti S Rao
Journal:  J Neuroimmunol       Date:  2004-08       Impact factor: 3.478

7.  Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages.

Authors:  U Traugott; E L Reinherz; C S Raine
Journal:  J Neuroimmunol       Date:  1983-06       Impact factor: 3.478

Review 8.  Microglial clearance function in health and disease.

Authors:  I Napoli; H Neumann
Journal:  Neuroscience       Date:  2008-07-01       Impact factor: 3.590

9.  Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function.

Authors:  Kuti Baruch; Aleksandra Deczkowska; Eyal David; Joseph M Castellano; Omer Miller; Alexander Kertser; Tamara Berkutzki; Zohar Barnett-Itzhaki; Dana Bezalel; Tony Wyss-Coray; Ido Amit; Michal Schwartz
Journal:  Science       Date:  2014-08-21       Impact factor: 47.728

10.  Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status.

Authors:  Daphne Y S Vogel; Elly J F Vereyken; Judith E Glim; Priscilla D A M Heijnen; Martina Moeton; Paul van der Valk; Sandra Amor; Charlotte E Teunissen; Jack van Horssen; Christine D Dijkstra
Journal:  J Neuroinflammation       Date:  2013-03-04       Impact factor: 8.322

View more
  24 in total

1.  Effects of lipoic acid on primary murine microglial cells.

Authors:  Priya Chaudhary; Gail Marracci; Edvinas Pocius; Danielle Galipeau; Brooke Morris; Dennis Bourdette
Journal:  J Neuroimmunol       Date:  2019-05-27       Impact factor: 3.478

2.  Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis.

Authors:  Robert P Lisak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-09       Impact factor: 11.205

Review 3.  Microglial Modulation as a Target for Chronic Pain: From the Bench to the Bedside and Back.

Authors:  Elena S Haight; Thomas E Forman; Stephanie A Cordonnier; Michelle L James; Vivianne L Tawfik
Journal:  Anesth Analg       Date:  2019-04       Impact factor: 5.108

4.  Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation.

Authors:  Changwen Zhang; Ayyiliath M Sajith; Xiaotian Xu; Jianxiong Jiang; J Phillip Bowen; Amol Kulkarni; Jiukuan Hao
Journal:  Bioorg Med Chem       Date:  2022-01-31       Impact factor: 3.641

5.  Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.

Authors:  Guillaume Dorcet; Hugo Migné; Damien Biotti; Chloé Bost; Fleur Lerebours; Jonathan Ciron; Emmanuel Treiner
Journal:  J Neurol       Date:  2022-06-02       Impact factor: 6.682

6.  Exploring reported genes of microglia RNA-sequencing data: Uses and considerations.

Authors:  Thecla A van Wageningen; Emma Gerrits; Sara Palacin I Bonson; Inge Huitinga; Bart J L Eggen; Anne-Marie van Dam
Journal:  Glia       Date:  2021-08-18       Impact factor: 8.073

Review 7.  Diversity and Function of Glial Cell Types in Multiple Sclerosis.

Authors:  Lucas Schirmer; Dorothy P Schafer; Theresa Bartels; David H Rowitch; Peter A Calabresi
Journal:  Trends Immunol       Date:  2021-02-13       Impact factor: 16.687

8.  Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis.

Authors:  Dennis Brown; Dorsa Moezzi; Yifei Dong; Marcus Koch; V Wee Yong
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

Review 9.  Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes.

Authors:  Tianci Chu; Lisa B E Shields; Wenxin Zeng; Yi Ping Zhang; Yuanyi Wang; Gregory N Barnes; Christopher B Shields; Jun Cai
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

10.  The pro-inflammatory microRNA miR-155 influences fibrillar β-Amyloid1 -42 catabolism by microglia.

Authors:  Macarena S Aloi; Katherine E Prater; Bryce Sopher; Stephanie Davidson; Suman Jayadev; Gwenn A Garden
Journal:  Glia       Date:  2021-03-10       Impact factor: 8.073

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.